Luteolin as a potential host-directed immunotherapy adjunct to isoniazid treatment of tuberculosis

Dhiraj Kumar Singh, Sultan Tousif, Ashima Bhaskar, Annu Devi, Kriti Negi, Barnani Moitra, Anand Ranganathan, Ved Prakash Dwivedi, Gobardhan Das

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


Tuberculosis (TB) remains a major health problem throughout the world with one third of the population latently infected and ∼2 million deaths annually. Current therapy consists of multiple antibiotics and a lengthy treatment regimen, which is associated with risk for the generation of drug-resistant Mycobacterium tuberculosis variants. Therefore, alternate host directed strategies that can shorten treatment length and enhance anti-TB immunity during the treatment phase are urgently needed. Here, we show that Luteolin, a plant-derived hepatoprotective immunomodulator, when administered along with isoniazid as potential host directed therapy promotes anti-TB immunity, reduces the length of TB treatment and prevents disease relapse. Luteolin also enhances long-term anti-TB immunity by promoting central memory T cell responses. Furthermore, we found that Luteolin enhances the activities of natural killer and natural killer T cells, both of which exhibit antitubercular attributes. Therefore, the addition of Luteolin to conventional antibiotic therapy may provide a means to avoid the development of drug-resistance and to improve disease outcome.

Original languageEnglish (US)
Article numbere1009805
JournalPLoS pathogens
Issue number8
StatePublished - Aug 2021

ASJC Scopus subject areas

  • Parasitology
  • Microbiology
  • Immunology
  • Molecular Biology
  • Genetics
  • Virology


Dive into the research topics of 'Luteolin as a potential host-directed immunotherapy adjunct to isoniazid treatment of tuberculosis'. Together they form a unique fingerprint.

Cite this